{"aliases":[{"type":"USBrandName","name":"Opdivo"},{"type":"CodeName","name":"CMAB819"},{"type":"Synonym","name":"nivolumab biosimilar CMAB819"},{"type":"Abbreviation","name":"NIVO"},{"type":"CodeName","name":"MDX-1106"},{"type":"CodeName","name":"ONO-4538"},{"type":"CodeName","name":"BMS-936558"},{"type":"Synonym","name":"nivolumab biosimilar ABP 206"},{"type":"Synonym","name":"nivolumab biosimilar BCD-263"},{"type":"CodeName","name":"ABP 206"},{"type":"CASRegistryName","name":"946414-94-4"}],"definition":{"html":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","text":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab","text":"Nivolumab"},"nciConceptId":"C68814","nciConceptName":"Nivolumab","termId":539733,"name":"nivolumab","firstLetter":"n","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"nivolumab"}